Tom MacDonald replies to Marisa de Andrade

doi:10.1136/bmj.b4281

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Tom MacDonald, professor of clinical pharmacology1

¹Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY

tom{at}memo.dundee.ac.uk

Thank you for allowing me to respond to Ms Andrade’s article about the Standard Care versus Celecoxib Outcome Trial (SCOT).1

SCOT was designed by me with Professor C J Hawkey (Nottingham University) and Professor Ian Ford (Glasgow University). The protocol is the property of Dundee University (the study sponsor) and was formally approved by the European Medicines Evaluation Agency (EMEA), as well as other regulatory bodies. The aim of the study is to assess the long term drug safety of non-steroidal anti-inflammatory drugs (NSAIDs) and is funded by Pfizer USA. In general the pharmaceutical industry does not see such safety studies as attractive commercially, which is why SCOT is led by an independent investigator (me) and …